Erythropoietin protects against renal ischemia/reperfusion injury in rats via inhibition of oxidative stress, inflammation and apoptosis
DOI:
https://doi.org/10.22317/jcms.v9i4.1405Keywords:
Ischemia, Reperfusion, Renal, Erythropoietin, AntioxidantsAbstract
Objective: Study investigates erythropoietin's nephroprotective effect in adult male rats with renal ischemia and reperfusion injury, examining biochemical parameters and renal tissue alterations.
Methods: twenty-eight male rats of Sprague Dawley randomized into four groups: Sham, Iscemia/Reperfusion, NS, and Erythropoietin. Sham group treated kidneys identically without clamping pedicles. Ischemia/Reperfusion group underwent midline laparotomy, 30 minutes ischemia, 2 hours reperfusion, Rats received NS vehicle for Erythropoietin 30 minutes before ischemia, Erythropoietin dose administered 30 minutes before ischemia/reperfusion. Operation performed under maintained anesthesia using ketamine and xylazine injections.
Results: Renal ischemia /reperfusion increased serum Cr, BUN, IL-1β, NF-kB, Caspase-3, while SOD, GSH, Bcl-2 decreased in induced rats. Erythropoietin treatment reduced Cr and BUN levels, Reduced inflammation, and inflammatory markers. Renal tissue antioxidant markers increased; apoptotic markers decreased. Significant increase in Bcl-2 antiapoptotic marker. Erythropoietin-treated group had significantly better renal histological score compared to induced group.
Conclusion: Erythropoietin protects against Ischemia/Reperfusion-mediated renal injury, possessing antioxidant, anti-inflammatory, and anti-apoptotic properties.
References
Jang, H.R. and H. Rabb, The innate immune response in ischemic acute kidney injury. Clinical immunology, 2009. 130(1): p. 41-50.
Sharfuddin, A.A. and B.A. Molitoris, Pathophysiology of ischemic acute kidney injury. Nature Reviews Nephrology, 2011. 7(4): p. 189-200.
Collard, C.D. and S. Gelman, Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. The Journal of the American Society of Anesthesiologists, 2001. 94(6): p. 1133-1138.
Wu, M.-Y., et al., New insights into the role of inflammation in the pathogenesis of atherosclerosis. International journal of molecular sciences, 2017. 18(10): p. 2034.
Ponticelli, C., Erratum: Ischaemia-reperfusion injury: A major protagonist in kidney transplantation (Nephrology Dialysis Transplantation (2014) 29: 6 (1134-1140. Nephrology Dialysis Transplantation, 2014. 29(8): p. 1612.
Zhong, D., et al., Ganoderma lucidum polysaccharide peptide prevents renal ischemia reperfusion injury via counteracting oxidative stress. Scientific reports, 2015. 5(1): p. 1-14.
Beker, B.M., et al., Novel acute kidney injury biomarkers: their characteristics, utility and concerns. International urology and nephrology, 2018. 50: p. 705-713.
Ja, K., unruh Ml and Murugan r: acute kidney injury. BMJ clin evid, 2011. 2001: p. 2011.
Rojas-Morales, P., et al., Fasting reduces oxidative stress, mitochondrial dysfunction and fibrosis induced by renal ischemia-reperfusion injury. Free Radical Biology and Medicine, 2019. 135: p. 60-67.
Van Avondt, K., E. Nur, and S. Zeerleder, Mechanisms of haemolysis-induced kidney injury. Nature Reviews Nephrology, 2019. 15(11): p. 671-692.
Dennis, J.M. and P.K. Witting, Protective role for antioxidants in acute kidney disease. Nutrients, 2017. 9(7): p. 718.
Kezić, A., N. Stajic, and F. Thaiss, Innate immune response in kidney ischemia/reperfusion injury: potential target for therapy. Journal of immunology research, 2017. 2017.
Park, J.S., et al., Small heterodimer partner attenuates hydrogen peroxide-induced expression of cyclooxygenase-2 and inducible nitric oxide synthase by suppression of activator protein-1 and nuclear factor-κB in renal proximal tubule epithelial cells. International journal of molecular medicine, 2017. 39(3): p. 701-710.
Tsagalis, G., Renal anemia: a nephrologist's view. Hippokratia, 2011. 15(Suppl 1): p. 39.
Priyadarshi, A. and J.I. Shapiro. Hematology: Issues in the dialysis patient: Erythropoietin resistance in the treatment of the anemia of chronic renal failure. in Seminars in dialysis. 2006. Wiley Online Library.
Kalantar-Zadeh, K., History of erythropoiesis-stimulating agents, the development of biosimilars, and the future of anemia treatment in nephrology. American journal of nephrology, 2017. 45(3): p. 235-247.
Suresh, S., et al., Erythropoietin-induced changes in bone and bone marrow in mouse models of diet-induced obesity. International journal of molecular sciences, 2020. 21(5): p. 1657.
Sheldon, R.A., et al., Erythropoietin treatment exacerbates moderate injury after hypoxia-ischemia in neonatal superoxide dismutase transgenic mice. Developmental neuroscience, 2017. 39(1-4): p. 228-237.
Tasar, P. and Y. Ozen, Effects of Recombinant Human Erythropoietin and 2-Mercaptoethane Sulfonate on Liver Ischemia-Reperfusion Injury in Rats. Experimental and Clinical Transplantation: Official Journal of the Middle East Society for Organ Transplantation, 2022.
Shawky, H.M., et al., Effect of recombinant erythropoietin on ischemia–reperfusion-induced apoptosis in rat liver. Journal of physiology and biochemistry, 2012. 68: p. 19-28.
Tiba, A.-T., H. Qassam, and N.R. Hadi, Semaglutide in renal ischemia-reperfusion injury in mice. Journal of Medicine and Life, 2023. 16(2): p. 317.
Erkılıç, E., et al., Does remifentanil attenuate renal ischemia–reperfusion injury better than dexmedetomidine in rat kidney? Drug Design, Development and Therapy, 2017: p. 677-683.
Kwak, J., et al., Erythropoietin ameliorates ischemia/reperfusion-induced acute kidney injury via inflammasome suppression in mice. International Journal of Molecular Sciences, 2020. 21(10): p. 3453.
Stroo, I., et al., Chemokine expression in renal ischemia/reperfusion injury is most profound during the reparative phase. International immunology, 2010. 22(6): p. 433-442.
Li, Y., et al., Hydralazine protects against renal ischemia-reperfusion injury in rats. European journal of pharmacology, 2019. 843: p. 199-209.
Tak, P.P. and G.S. Firestein, NF-κB: a key role in inflammatory diseases. The Journal of clinical investigation, 2001. 107(1): p. 7-11.
Zhang, H. and S.-C. Sun, NF-κB in inflammation and renal diseases. Cell & bioscience, 2015. 5(1): p. 1-12.
Zhang, J., et al., Erythropoietin pretreatment ameliorates renal ischaemia‐reperfusion injury by activating PI3K/Akt signalling. Nephrology, 2015. 20(4): p. 266-272.
Hu, L., et al., Erythropoietin ameliorates renal ischemia and reperfusion injury via inhibiting tubulointerstitial inflammation. Journal of Surgical Research, 2012. 176(1): p. 260-266.
Malek, M. and M. Nematbakhsh, Renal ischemia/reperfusion injury; from pathophysiology to treatment. Journal of renal injury prevention, 2015. 4(2): p. 20.
Xu, N., et al., Reactive oxygen species in renal vascular function. Acta Physiologica, 2020. 229(4): p. e13477.
Tang, Y., et al. Recombinant human erythropoietin restrains oxidative stress in streptozotocin-induced diabetic rats exposed to renal ischemia reperfusion injury. in Transplantation Proceedings. 2019. Elsevier.
Sun, Z., et al., Dexmedetomidine attenuates spinal cord ischemia–reperfusion injury through both anti-inflammation and anti-apoptosis mechanisms in rabbits. Journal of Translational Medicine, 2018. 16: p. 1-11.
Liu, H., et al., Overexpression of TIMP3 protects against cardiac ischemia/reperfusion injury by inhibiting myocardial apoptosis through ROS/Mapks pathway. Cellular Physiology and Biochemistry, 2017. 44(3): p. 1011-1023.
Hu, L., et al., HBx sensitizes cells to oxidative stress-induced apoptosis by accelerating the loss of Mcl-1 protein via caspase-3 cascade. Molecular cancer, 2011. 10: p. 1-16.
Renault, T.T. and J.E. Chipuk, Death upon a kiss: mitochondrial outer membrane composition and organelle communication govern sensitivity to BAK/BAX-dependent apoptosis. Chemistry & biology, 2014. 21(1): p. 114-123.
Yang, C.W., et al., Preconditioning with erythropoietin protects against subsequent ischemia‐reperfusion injury in rat kidney. The FASEB Journal, 2003. 17(12): p. 1754-1755.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
